Our Stories
Latest News
Innovation
Caring & Giving
Personal Stories
Health & Wellness
Our Heritage
Our Company
About J&J
Our Credo
Our Leadership Team
Corporate Governance
Diversity & Inclusion
Empowering Women
Innovation at J&J
Office of the Chief Medical Officer
J&J Health and Wellness Solutions
Policies & Statements
Code of Business Conduct
Corporate Reports
Products
Consumer Products
Medical Devices
Pharmaceutical Products
Procurement
Value Pillars
Supplier Diversity
Supplier Standards
Careers
What We Do
How We Hire
Job Spotlight
Employee Benefits
Students
Innovation
Career Stories
Media Center
Investors
Corporate Governance
Quarterly Results
SEC Filings
News Releases
Pharmaceutical Pipeline
2016 Health for Humanity Report
Stock Information
Webcasts & Presentations
Our Societal Impact
Global Community Impact
Global Public Health
Global Environmental Health
Citizenship & Sustainability Reporting
Follow Us
Facebook
Twitter
YouTube
LinkedIn
Explore more Johnson & Johnson sites:
Australia
Argentina
Brazil
Canada
Chile
China
Colombia
Costa Rica
Ecuador
Germany
India
Italy
Japan
Mexico
New Zealand / Pacific
Paraguay
Peru
Philippines
Russia
Switzerland
German
English
French
Italian
Uruguay
United States
Venezuela
Press Release Archive
+
View Filters
All Topics
Caring & Giving
Health & Wellness
Innovation
Our Company
Our Heritage
Our Products
All Dates
Last 30 Days
Last 90 Days
Last Year
Sort by Newest
Sort by Oldest
Products & Operating Company
October 18, 2012
Crohn’s Disease Patients Refractory To Tumor Necrosis Factor Inhibitors Showed Improvement In Disease With STELARA® Treatment
STELARA Phase 2b Crohn’s Disease Study Published in The New England Journal of Medicine
October 17, 2012
Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2012
October 16, 2012
Johnson & Johnson Reports 2012 Third-Quarter Results
Sales of $17.1 Billion increased 6.5% Versus 2011 Third Quarter; Third-Quarter EPS was $1.05Excluding Special Items, 2012 Third-Quarter EPS of $1.25 increased 0.8%*
Products & Operating Company
October 10, 2012
Cordis Corporation Announces One-Year Results from the STROLL Trial
Trial Assesses the Safety and Efficacy of the S.M.A.R.T.® Nitinol Self-Expandable Stent System in the Superficial Femoral Artery*
Products & Operating Company
October 02, 2012
First Results from Phase 3 CANVAS Trial Show Canagliflozin as Add-on Therapy to Insulin Lowered Blood Sugar Levels in Patients with Type 2 Diabetes at an Elevated Risk for Cardiovascular Disease
Canagliflozin also shown effective and generally well-tolerated in patients with type 2 diabetes aged 55 to 80 in separate Phase 3 study
Products & Operating Company
October 02, 2012
Janssen Announces Worldwide Agreement To Develop And Commercialize JAK Inhibitor For Immunological Diseases
Orally Administered Investigational Therapy Expands Global Immunology Portfolio
Products & Operating Company
October 01, 2012
Janssen Presents Sustainable Health Care Programs at CleanMed Europe Conference, Malmo, Sweden
Products & Operating Company
October 01, 2012
Depuy Mitek Launches Next Generation Rotator Cuff Anchor
New HEALIX ADVANCE™ Family of Suture Anchors Offers High Strength Repair, Surgical Versatility and Ease of Use
October 01, 2012
James E. Burke, Former Chairman and CEO of Johnson & Johnson, Dies at 87
Products & Operating Company
September 30, 2012
New ZYTIGA® (abiraterone acetate) Data on Pain and Function Presented at the ESMO 2012 Congress (European Society for Medical Oncology)
New Analyses from Phase 3 COU-AA-302 Study Also Suggest Radiographic Progression-Free Survival Positively Associated with Overall Survival
See More Press Releases